A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy

The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Failed or Intolerance to Standard Therapy

Trial Details

NCT ID
NCT06742892
Phase
PHASE2
Sponsor
Shanghai Henlius Biotech
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • HLX43 DOSE 1
  • HLX43 DOSE 2
  • HLX43 DOSE 3
Locations (sample)
  • Hunan, Hunan, China

Key Eligibility Criteria

  • Volunteer to participate in clinical research;To fully understand and understand this study and to sign the Informed Consent Form (ICF);Willing to …
  • The age of signing ICF is ≥ 18 years old and ≤ 75 years old,regardless of gender;
  • Hepatocellular carcinoma (HCC) confirmed by histopathology or cytology, or clinically meeting the American Association of Hepatology (AASLD) criter…
  • Previous failure or progression of at least one standard systemic therapy for hepatocellular carcinoma (standard therapy refers to PD-1/ L1-based c…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →